TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28182863

Group type: EXPERIMENTAL
Intervention: CHW-delivered diabetes self-management intervention
Number of subjects: 287

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 287
Study: 25486375

Group type: EXPERIMENTAL
Intervention: Video Interaction Guidance (VIG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 150
Study: 24027945

Group type: EXPERIMENTAL
Intervention: Repeated suppression group (3 suppression and 3 think free phases)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suppress think free group (1 suppression phase followed by 5 think free phases)
Number of subjects: 0
Study: 22029746

Group type: EXPERIMENTAL
Intervention: Caseload midwifery care
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard or routine hospital care
Number of subjects: 750
Study: 19285581

Group type: EXPERIMENTAL
Intervention: No Lifting policy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before and after intervention periods
Number of subjects: 0
Study: 17016713

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lorazepam (dose-dependent)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lorazepam-induced increase in insular cortex activation
Number of subjects: 15
Study: 12654404

Group type: COMPARATOR
Intervention: Partially unblinded placebo-controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partially unblinded active-controlled drug trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods for estimating preference effects
Number of subjects: 0
Study: 12219003

Group type: EXPERIMENTAL
Intervention: Cuffed ePTFE graft
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard ePTFE graft
Number of subjects: 48
Study: 9605897

Group type: EXPERIMENTAL
Intervention: ciprofloxacin-rifampin
Number of subjects: 33

Group type: COMPARATOR
Intervention: ciprofloxacin-placebo
Number of subjects: 33
Study: 7974344

Group type: EXPERIMENTAL
Intervention: High-fat diet (50% of energy)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 17
Study: 2608693

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (8 capsules/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (8 capsules)
Number of subjects: 47
Study: 128707

Group type: EXPERIMENTAL
Intervention: Dipropylacetic acid (DPA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dipropylacetic acid (DPA) and gamma-aminobutyric acid (GABA)
Number of subjects: 8
Study: 31804414

Group type: EXPERIMENTAL
Intervention: Surgical stabilization of rib fractures (SSRF) within 72 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Medical management (nonoperative group)
Number of subjects: 110
Study: 29695206

Group type: EXPERIMENTAL
Intervention: Oral paracetamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 60
Study: 28231827

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (6 months duration) designed to improve strength, balance, and walking retraining.
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care group (control group).
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (6 months duration).
Number of subjects: 114
Study: 25724520

Group type: EXPERIMENTAL
Intervention: Cetuximab (6-week course, weekly) with cisplatin-based radiochemotherapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Cisplatin-based radiochemotherapy alone
Number of subjects: 78
Study: 23506695

Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin training for three months
Number of subjects: 464

Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 464
Study: 21679446

Group type: EXPERIMENTAL
Intervention: DNAT plus learning modules (intervention group)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Online self-directed learning (control group)
Number of subjects: 650
Study: 18446392

Group type: EXPERIMENTAL
Intervention: Perindopril-based regimen
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 6105
Study: 16443886

Group type: EXPERIMENTAL
Intervention: Mean blood glucose (MBG)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Biological variation (BV)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Glucose instability (SD of blood glucose [SDBG])
Number of subjects: 1441
Study: 15047787

Group type: EXPERIMENTAL
Intervention: Experience Corps program (older adult volunteers serving 15 hours or more per week)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1194
Study: 11505961

Group type: EXPERIMENTAL
Intervention: 2,800 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 1,700 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 2,200 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 1,100 ppm F‐ ion (as sodium fluoride) dentifrice
Number of subjects: 1200
Study: 9209950

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (40 Gy with 5-FU as a sensitizing agent)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 6 months of chemotherapy (5-FU and folinic acid)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 221

Group type: COMPARATOR
Intervention: No-adjuvant treatment (control)
Number of subjects: 221
Study: 29310653

Group type: EXPERIMENTAL
Intervention: High-dose soy lecithin (1200 mg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low-dose soy lecithin (600 mg/day)
Number of subjects: 96
Study: 27359128

Group type: EXPERIMENTAL
Intervention: Sleep-deprived participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Well-rested participants
Number of subjects: 0
Study: 23946126

Group type: EXPERIMENTAL
Intervention: Transtympanic 2% L‐N‐Acetylcysteine (L‐NAC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control ear (no treatment)
Number of subjects: 11
Study: 22095569

Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions (3 annual treatments)
Number of subjects: 12
Study: 19334041

Group type: EXPERIMENTAL
Intervention: Second generation antidepressants
Number of subjects: 3709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3709
Study: 17252311

Group type: EXPERIMENTAL
Intervention: Aromatic amino acids (AAAs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Branched-chain amino acids (BCAAs)
Number of subjects: 30
Study: 14734433

Group type: EXPERIMENTAL
Intervention: Evidence-based algorithms for nutritional support in the ICU (implemented in 7 intervention hospitals)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control hospitals (n = 214)
Number of subjects: 499
Study: 11452819

Group type: EXPERIMENTAL
Intervention: Drainage after thyroid surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: No drainage after thyroid surgery
Number of subjects: 60
Study: 9568553

Group type: EXPERIMENTAL
Intervention: Academic detailing (AD) alone
Number of subjects: 4995

Group type: EXPERIMENTAL
Intervention: Combination of Academic detailing (AD) and Continuous Quality Improvement (CQI) teams
Number of subjects: 4995

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4995
Study: 8067507

Group type: EXPERIMENTAL
Intervention: Expectation of alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actual alcohol consumption
Number of subjects: 0
Study: 3055074

Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg bolus followed by 50 micrograms/kg/h infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (preservatives of the naloxone preparation)
Number of subjects: 8
Study: 5481219

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 891

Group type: COMPARATOR
Intervention: Thermography
Number of subjects: 891

Group type: COMPARATOR
Intervention: 70-mm mammography
Number of subjects: 891
Study: 31912202

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous adrenaline
Number of subjects: 8016

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8016
Study: 30715100

Group type: EXPERIMENTAL
Intervention: Consensus orthostatic hypotension (OH) measurements
Number of subjects: 4268

Group type: EXPERIMENTAL
Intervention: M2 (3 minutes) measurement
Number of subjects: 4268

Group type: EXPERIMENTAL
Intervention: Later measurements of OH
Number of subjects: 4268

Group type: COMPARATOR
Intervention: BP treatment goal
Number of subjects: 4268

Group type: EXPERIMENTAL
Intervention: All measures of consensus OH
Number of subjects: 4268

Group type: EXPERIMENTAL
Intervention: All measurements of OH
Number of subjects: 4268
Study: 28398499

Group type: EXPERIMENTAL
Intervention: R-CHOP-14
Number of subjects: 604

Group type: COMPARATOR
Intervention: R-CHOP-21
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Combined analysis of MYC-R and DHL
Number of subjects: 604
Study: 25941982

Group type: EXPERIMENTAL
Intervention: Clinical trial intervention involving undergraduate and doctoral students
Number of subjects: 22
Study: 23640665

Group type: COMPARATOR
Intervention: Small-incision open cholecystectomy (SIOC)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 333
Study: 21570660

Group type: EXPERIMENTAL
Intervention: Cemented humeral fixation
Number of subjects: 161

Group type: COMPARATOR
Intervention: Uncemented humeral fixation
Number of subjects: 161
Study: 18054688

Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulfate, 80 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17203478

Group type: EXPERIMENTAL
Intervention: CW (continuous wave EMF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PM (pulse modulated EMF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: SHAM (no EMF)
Number of subjects: 72
Study: 15295613

Group type: EXPERIMENTAL
Intervention: Candesartan monotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Candesartan plus ACEI/amlodipine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Candesartan plus ACEI
Number of subjects: 58

Group type: COMPARATOR
Intervention: Candesartan plus amlodipine
Number of subjects: 58
Study: 11306743

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus G-CSF
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G-CSF alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tumor cell contamination presence
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Number of metastasis
Number of subjects: 38
Study: 9399229

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 91

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 91
Study: 7959290

Group type: EXPERIMENTAL
Intervention: Radical therapy (Group A)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conservative therapy (Group B)
Number of subjects: 8
Study: 3605694

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine pretreatment (0.05 mg/kg) followed by succinylcholine (1.5 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal saline (1 ml) followed by succinylcholine (1.5 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.7 mg/kg of succinylcholine without d‐tubocurarine pretreatment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: d‐tubocurarine pretreatment (0.05 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-pretreated groups (C‐2 and T‐2)
Number of subjects: 75
Study: 31982073

Group type: EXPERIMENTAL
Intervention: Two doses of combined measles-mumps-rubella-varicella vaccine (MMR+V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One dose of monovalent varicella vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMR+V group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMR group
Number of subjects: 0
Study: 31212214

Group type: EXPERIMENTAL
Intervention: Overdose responding self-efficacy assessment
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Witnessing an overdose in the past year
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Experience with naloxone training
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Receiving and using naloxone
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Apprehension with particular response behaviors (e.g. rescue breathing)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 424
Study: 28100182

Group type: EXPERIMENTAL
Intervention: Fingolimod first dose
Number of subjects: 3951

Group type: EXPERIMENTAL
Intervention: Continuous Holter ECG monitoring
Number of subjects: 3951
Study: 26030423

Group type: EXPERIMENTAL
Intervention: Continuous stationary cycling (CYC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rugby small-sided games (SSG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 23562361

Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 160
Study: 21911572

Group type: EXPERIMENTAL
Intervention: ACHN-490 injection, 1 mg/kg body weight followed by ascending doses of 4, 7, 11, and 15 mg/kg for 10, 10, 5, and 3 days respectively in Study 1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ACHN-490 injection, 15 mg/kg for 5 days in Study 2
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19622708

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 45
Study: 17076985

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1000 mg daily for 12 months
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 1000 mg daily for 24 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 130
Study: 15582080

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (200 microg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo (without 5‐fluorouracil and LMWH)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil and LMWH
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 11527868

Group type: EXPERIMENTAL
Intervention: Supervision for standard treatment guidelines (STG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Supervision for stock management
Number of subjects: 62

Group type: COMPARATOR
Intervention: No supervision (control group)
Number of subjects: 62
Study: 9691859

Group type: EXPERIMENTAL
Intervention: Auditory examples of two semantic categories presented through headphones during certain stages of the procedure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Auditory examples of two semantic categories presented through headphones during steady-state anaesthesia
Number of subjects: 100
Study: 7892419

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3340471

Group type: EXPERIMENTAL
Intervention: Scheduled awakenings
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Systematic ignoring
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 31039765

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment as Usual (TAU)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 160
Study: 29301585

Group type: EXPERIMENTAL
Intervention: Biomarker controlled treatment advisory algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26801063

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 μg) with standard regimen (0-1-6 month)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (60 μg) with 2-dose regimen (0-1 month)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (60 μg) with 2-dose regimen (0-2 month)
Number of subjects: 3
Study: 23495792

Group type: EXPERIMENTAL
Intervention: Side-fenestrated catheter
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 250
Study: 21792863

Group type: EXPERIMENTAL
Intervention: EGFR testing and first-line treatment with gefitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-line treatment with gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (first-line treatment with chemotherapy followed by gefitinib as second-line treatment)
Number of subjects: 0
Study: 19910718

Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (3-12 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17244770

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg oral dose
Number of subjects: 0
Study: 15614126

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 12
Study: 12518491

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro
Number of subjects: 87
Study: 9784659

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no cromolyn sodium)
Number of subjects: 16
Study: 7894551

Group type: EXPERIMENTAL
Intervention: Captopril, an angiotensin-converting enzyme inhibitor, administered 3 to 16 days after acute myocardial infarction.
Number of subjects: 0
Study: 2165890

Group type: EXPERIMENTAL
Intervention: Starvation for 12-14 h
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Starvation for 30-36 h
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Starvation for 60-66 h
Number of subjects: 19
Study: 356738

Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31618863

Group type: EXPERIMENTAL
Intervention: 30 g of pure whey protein isolate (L)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 70 g of pure whey protein isolate (H)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0 g of protein (C)
Number of subjects: 18
Study: 27829249

Group type: EXPERIMENTAL
Intervention: Decoy receptor 3 (DcR3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Trefoil factor 3 (TFF3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Midkine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 26122108

Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA with 28 mm articulation
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA with 36 mm articulation
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Delta ceramic-on-ceramic THA (both groups)
Number of subjects: 345
Study: 24292904

Group type: EXPERIMENTAL
Intervention: Mobile learning device (Samsung NC10 Netbook) with interactive exercises
Number of subjects: 55

Group type: COMPARATOR
Intervention: Traditional library exercise
Number of subjects: 55
Study: 21673045

Group type: EXPERIMENTAL
Intervention: Oral periodic presumptive treatment (PPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19843683

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 16707869

Group type: EXPERIMENTAL
Intervention: Salivary pellicle formed on enamel pretreated with unstimulated human saliva for 1 hour or more
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salivary pellicle formed on dentine pretreated with unstimulated human saliva for 2 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group exposed to water for the same times as the intervention
Number of subjects: 0
Study: 14713918

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg daily and zafirlukast 20 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine 10 mg daily and placebo
Number of subjects: 0
Study: 11158471

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 273
Study: 9209776

Group type: COMPARATOR
Intervention: Sumatriptan 5 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sumatriptan 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sumatriptan 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sumatriptan 20 mg (multiple doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sumatriptan (overall)
Number of subjects: 32
Study: 7802852

Group type: EXPERIMENTAL
Intervention: Alpidem (50 mg, three times a day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Alprazolam (0.5 mg, three times a day)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 122
Study: 2439808

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29861725

Group type: EXPERIMENTAL
Intervention: GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and < 7.0 mmol/L postprandial)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GDM2 (less tight glycaemic targets, fasting blood glucose < 5.3 mmol/L and < 7.8 mmol/L postprandial)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GDM2
Number of subjects: 41
Study: 27475042

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 300
Study: 24390775

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (transfusion when hemoglobin fell below 7 g/dL)
Number of subjects: 921

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (transfusion when hemoglobin fell below 9 g/dL)
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 921

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 921